Table 1. Clinical data of patients with MCDs.
| Type | Case | Sex | Age (years) | Duration of epilepsy (years) | Seizure frequency (times/year) | Antiepileptic drugs |
|---|---|---|---|---|---|---|
| GMH | 1 | M | 18 | 1 | 3 | LEV, OXC, VPA |
| 2 | M | 9 | 7 | Total 2 | LEV, OXC | |
| 3 | M | 10 | 1 | 3 | LEV, OXC | |
| 4 | F | 30 | 6 | 1–2 | LEV | |
| 5 | M | 15 | 2 | 12–24 | LEV, VPA | |
| 6 | F | 7 | 4 | Total 1 | LEV | |
| 7 | M | 22 | 1 | 4–6 | OXC | |
| 8 | F | 26 | 3 | Total 2 | LEV | |
| 9 | M | 12 | 3 | 2 | LEV | |
| 10 | M | 39 | 15 | 3 | VPA | |
| FCD | 11 | M | 41 | 28 | Total 3 | LEV, CBZ |
| 12 | F | 31 | 20 | 60 | OXC, LEV, TPM | |
| 13 | M | 30 | 4 | 0–1 | LEV, OXC | |
| 14 | M | 40 | 4 | 4–6 | LEV, OXC | |
| 15 | F | 20 | 5 | 12 | OXC | |
| 16 | F | 24 | 10 | 4–5 | LEV | |
| 17 | M | 34 | 28 | 3–4 | OXC | |
| 18 | F | 31 | 10 | 24–36 | OXC | |
| 19 | F | 10 | 3 | 36 | LEV | |
| 20 | F | 27 | 13 | 120 | LEV, OXC | |
| PMG | 21 | M | 31 | 4 | 132 | VPA |
| 22 | M | 18 | 10 | 2–3 | OXC | |
| 23 | F | 21 | 13 | 12 | OXC | |
| 24 | M | 19 | 0.5 | Total 2 | OXC | |
| 25 | F | 12 | 4 | 2–6 | LEV | |
| 26 | M | 38 | 17 | 48 | OXC, LEV | |
| 27 | F | 10 | 1 | 10 | OXC | |
| 28 | M | 8 | 3 | 52 | OXC, LEV | |
| 29 | M | 15 | 7 | 24–36 | LEV, OXC |
MCDs, malformations of cortical development; GMH, gray matter heterotopia; M, male; LEV, levetiracetam; OXC, oxcarbazepine; VPA, valproate; F, female; FCD, focal cortical dysplasia; CBZ, carbamazepine; TPM, topiramate; PMG, polymicrogyria.